Artivion Inc., a leading company in cardiac and vascular surgery, has announced its entry into privately negotiated exchange agreements with certain holders of its 4.250% Convertible Senior Notes due 2025. The company plans to repurchase approximately $95 million in principal amount of these notes in exchange for shares of its common stock. The exact number of shares will be determined based on the trading price of the stock over a four-day period starting May 15, 2025. At the closing stock price of $28.91, this would translate to approximately 4.1 million shares. Additionally, Artivion will pay cash for accrued and unpaid interest to the note holders. The transaction is expected to close around May 28, 2025, pending customary conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.